financetom
Business
financetom
/
Business
/
Alkane And Mandalay Combine In A $707 Million 'Merger Of Equals'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alkane And Mandalay Combine In A $707 Million 'Merger Of Equals'
May 25, 2025 10:12 PM

Australia's Alkane Resources ( ALKEF )   and Canada's Mandalay Resources ( MNDJF )   have announced a "merger of equals "in an all-share transaction valued at approximately AU$1.01 billion ($707 million), creating a diversified gold and antimony producer with global reach.

The newly combined company will retain the Alkane name and remain listed in Australia, but it will seek a dual listing on the Toronto Stock Exchange.

"The transaction will take Alkane to a new level, bringing together two companies with complementary assets and a shared vision for growth," said Nick Earner, Alkane Managing Director. "Mandalay's two high-quality mines match the attributes of Tomingley: a proven history of consistent production, cash generation and exploration upside."

The merger brings together three producing assets across premier mining jurisdictions. Alkane contributes to the Tomingley gold mine in New South Wales, which is currently ramping up production after an expansion.

Mandalay adds its Costerfield gold-antimony mine in Victoria—Australia's only antimony producer—and the Björkdal underground gold mine in Sweden.

The combined group is projected to produce approximately 160,000 gold-equivalent ounces in 2025, increasing to over 180,000 ounces in 2026. Additionally, all-in sustaining costs (AISC) are forecast to drop from AU$2,750/oz in 2025 to AU$2,160/oz in 2026, reflecting improved scale and efficiency.

Frazer Bourchier, Mandalay's President and CEO, noted the merger "presents a compelling opportunity for Mandalay shareholders to accelerate value creation through increased capital markets scale, liquidity and a growing diversified asset base."

"The transaction aligns with our vision to create a mid-tier gold and antimony producer with mines in premier operating jurisdictions and with our strategy for continued growth," he said.

Alkane's Earner will lead the new entity, headquartered in Australia, while industry veteran Andrew Quinn will lead the board, which comprises three directors nominated by Mandalay and two by Alkane.

The pro forma balance sheet includes a robust cash position of AU$188 million ($120 million) as of March 31, 2025, allowing it to pursue further organic growth and strategic opportunities, including advancing Alkane's Boda-Kaiser copper-gold project.

Mandalay shareholders will receive 7.875 Alkane shares for each share they hold, resulting in a 55% stake in the new company, while Alkane shareholders will retain 45%. The transaction has the unanimous support of both boards and major shareholders and is subject to regulatory, shareholder, and court approvals.

The companies expect the deal to close in the second half of 2025, pending regulatory approvals.

Read Next:

KoBold Metals Prepares Billions To Develop Ethical Sources Of Critical Metals In DR Congo

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
1911 Gold Receives $1.7 Million from Early Exercise of Warrants
1911 Gold Receives $1.7 Million from Early Exercise of Warrants
Sep 27, 2024
08:59 AM EDT, 09/26/2024 (MT Newswires) -- 1911 Gold ( AUMBF ) said on Thursday that it received nearly $1.7 million from the early exercise of warrants by 2176423 Ontario, a corporation that is beneficially owned by Eric Sprott. 1911 said the funds will help the company finalize plans for its upcoming drill program in mid-October at the Rice Lake...
PTC Therapeutics Granted FDA Fast Track Designation for Huntington's Disease Program
PTC Therapeutics Granted FDA Fast Track Designation for Huntington's Disease Program
Sep 27, 2024
08:59 AM EDT, 09/26/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Thursday its PTC518 program for the treatment of Huntington's disease has received fast track designation from the US Food and Drug Administration. The biopharmaceutical company reported in June positive results from a 12-month readout of a study evaluating PTC518 in Huntington's disease patients. Shares were up more...
Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease
Acumen, Lonza Extend Deal to Add Manufacturing of Sabirnetug for Alzheimer's Disease
Sep 27, 2024
08:58 AM EDT, 09/26/2024 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) said Thursday that it has extended its partnership with Lonza to offer drug product manufacturing for clinical and potential commercial supply from the latter's Visp, Switzerland, facility to treat Alzheimer's disease. The extended agreement requires Lonza to produce cGMP drug product of sabirnetug for the current and future...
Enanta Pharmaceuticals Says Phase 2a Trial of Potential RSV Treatment Meets Endpoints
Enanta Pharmaceuticals Says Phase 2a Trial of Potential RSV Treatment Meets Endpoints
Sep 27, 2024
08:58 AM EDT, 09/26/2024 (MT Newswires) -- Enanta Pharmaceuticals ( ENTA ) said Thursday that a phase 2a study evaluating EDP-323 in adults with respiratory syncytial virus, or RSV, met its primary and secondary endpoints. Reductions of 85% to 87% in viral load area under the curve, 97% to 98% in infectious viral load AUC, and 66% to 78% in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved